TXR-611

TXR-611 is an investigational **small-molecule** therapeutic candidate that has been reported by twoXAR Pharmaceuticals for the treatment of nonalcoholic steatohepatitis. Publicly available information indicates that it emerged from twoXAR's discovery efforts as one of two novel lead compounds and showed preclinical activity in hepatic stellate cell assays and mouse models of steatohepatitis and fibrosis, with reported reductions in steatosis, ballooning, collagen deposition, liver weight, and NAFLD activity score. However, the **precise molecular target and mechanism of action have not been publicly disclosed** in the accessible sources, so TXR-611 is best characterized as a preclinical, mechanism-undisclosed NASH/MASH small molecule associated with twoXAR's liver disease pipeline.